Drug Trial Radar · NCT06608927
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
610
Planned (sponsor's estimate)
Start
Dec 13, 2024
Primary completion
Nov 30, 2030
Study completion Nov 30, 2030
Sponsor
- Lead sponsor
- Arcus Biosciences, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Taiho Pharmaceutical Co., Ltd.
- First posted
- Sep 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.
Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
QuemliclustatDrug
Administered as specified in the treatment arm
PlaceboDrug
Administered as specified in the treatment arm
Nab-paclitaxelDrug
Administered as specified in the treatment arm
GemcitabineDrug
Administered as specified in the treatment arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to 72 months
Locations
111 sites in 13 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona
Research Site
Tucson, Arizona
Research Site
La Jolla, California
Research Site
Los Alamitos, California
Research Site
Los Angeles, California
Research Site
Roseville, California
Research Site
San Francisco, California
Research Site
Santa Monica, California
Research Site
Denver, Colorado
Research Site
New Haven, Connecticut
Research Site
Jacksonville, Florida
Research Site
Miami, Florida
Research Site
Atlanta, Georgia
Research Site
Atlanta, Georgia
Research Site
Arlington Heights, Illinois
Research Site
Chicago, Illinois
Research Site
Indianapolis, Indiana
Research Site
Wichita, Kansas
Research Site
Baton Rouge, Louisiana
Research Site
Ann Arbor, Michigan
Research Site
Grand Rapids, Michigan
Research Site
Minneapolis, Minnesota
Research Site
Rochester, Minnesota
Research Site
Hattiesburg, Mississippi
Research Site
Kansas City, Missouri
Research Site
Omaha, Nebraska
Research Site
New Brunswick, New Jersey
Research Site
Buffalo, New York
Research Site
New York, New York
Research Site
New York, New York
Research Site
New York, New York
Research Site
New York, New York
Research Site
Rochester, New York
Research Site
Cleveland, Ohio
Research Site
Oklahoma City, Oklahoma
Research Site
Philadelphia, Pennsylvania
Research Site
Pittsburgh, Pennsylvania
Research Site
Nashville, Tennessee
Research Site
Austin, Texas
Research Site
Dallas, Texas
Showing 40 of 111 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.